{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-26-013663","form_type":"8-K","ticker":"IMMX","cik":"0001873835","company_name":"Immix Biopharma, Inc.","filed_at":"2026-03-30T23:59:59+00:00","discovered_at":"2026-05-14T18:02:36.632353+00:00","generated_at":"2026-05-15T08:26:47.555793+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Immix Biopharma completes NEXICART-2 enrollment; topline results Q3 2026","bullets":["Enrollment complete for 40-patient BLA-enabling Phase 2 trial NEXICART-2 (NCT06097832) in relapsed/refractory AL Amyloidosis.","Topline results expected Q3 2026, followed by BLA submission and planned commercial launch for NXC-201.","Onboarded Chief Medical Officer Richard Graydon, MD, PhD, formerly of Merck and Johnson & Johnson.","NXC-201 has FDA Breakthrough Therapy, RMAT, and Orphan Drug Designations; market for AL Amyloidosis estimated at $6B in 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-013663","json":"https://secwatch.observer/filing/0001493152-26-013663.json","markdown":"https://secwatch.observer/filing/0001493152-26-013663.md","text":"https://secwatch.observer/filing/0001493152-26-013663.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1873835/000149315226013663/0001493152-26-013663-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1873835/000149315226013663/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T08:26:47.555793+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}